Analysis of results showed that (Figure 11A–D) the expression of ZFP36 (normal vs. Stage I: p = 0.0138013; normal vs. stage II: p = 0.031858), FAP (normal vs. stage I: p = 0.049636; normal vs. stage II: p < 0.001), and CCT6A (normal vs. stage I: p < 0.001; normal vs. stage II: p < 0.001) in normal tissues of GC patients and tumor tissues of GC patients with clinical pathology stage 1 and stage 2 were statistically significant (both p < 0.05). This evidence concerns the gene ZFP36 and neoplasm.